Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M12,271Revenue $M3,324Net Margin (%)8.9Z-Score3.6
Enterprise Value $M12,791EPS $3.8Operating Margin %23.4F-Score6
P/E(ttm))44.7Cash Flow Per Share $8.0Pre-tax Margin (%)13.4Higher ROA y-yN
Price/Book6.810-y EBITDA Growth Rate %11.2Quick Ratio2.7Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %8.5Current Ratio3.3Lower Leverage y-yY
Price/Cash Flow12.2y-y EBITDA Growth Rate %-51.3ROA % (ttm)5.8Higher Current Ratio y-yN
Dividend Yield %0.5Insider Buy (3m)0ROE % (ttm)15.6Less Shares Outstanding y-yY
Payout Ratio %23.0Shares Outstanding M74.3ROI % (ttm)5.1Gross Margin Increase y-yY

Gurus Latest Trades with BCR

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impact Price Range
(Average)*
Current Price Change from Averagedown Comment Current Shares
BCRRay Dalio 2014-12-31 Reduce-0.01%$144.77 - $172.68
($161.89)
$ 165.242%Reduce -20.22%47,138
BCRYacktman Focused Fund 2014-12-31 Reduce-0.82%$144.77 - $172.68
($161.89)
$ 165.242%Reduce -24.93%1,614,000
BCRDonald Yacktman 2014-12-31 Reduce-1.17%$144.77 - $172.68
($161.89)
$ 165.242%Reduce -30.85%4,455,796
BCRJohn Hussman 2014-12-31 Reduce-0.06%$144.77 - $172.68
($161.89)
$ 165.242%Reduce -33.33%10,000
BCRYacktman Fund 2014-12-31 Reduce-1.42%$144.77 - $172.68
($161.89)
$ 165.242%Reduce -35.51%2,096,000
BCRJoel Greenblatt 2014-12-31 Reduce-0.31%$144.77 - $172.68
($162.11)
$ 165.242%Reduce -93.82%14,178
BCRRobert Olstein 2014-12-31 Sold Out -0.63%$144.77 - $172.68
($161.89)
$ 165.242%Sold Out0
BCRJohn Hussman 2014-09-30 Buy 0.18%$142.3 - $153.13
($147.81)
$ 165.2411%New holding15,000
BCRJoel Greenblatt 2014-09-30 Add0.27%$142.3 - $153.13
($147.81)
$ 165.2411%Add 470.83%229,325
BCRRay Dalio 2014-09-30 Add0.04%$142.3 - $153.13
($147.81)
$ 165.2411%Add 115.75%59,086
BCRDonald Yacktman 2014-09-30 Reduce-0.15%$142.3 - $153.13
($147.81)
$ 165.2411%Reduce -3.85%6,443,334
BCRYacktman Focused Fund 2014-09-30 Reduce-0.22%$142.3 - $153.13
($147.81)
$ 165.2411%Reduce -6.52%2,150,000
BCRJoel Greenblatt 2014-06-30 Add0.05%$136.23 - $149.25
($142.86)
$ 165.2414%Add 187.29%40,174
BCRRobert Olstein 2014-06-30 Add0.15%$136.23 - $149.25
($142.86)
$ 165.2414%Add 26.67%38,000
BCRYacktman Fund 2014-06-30 Reduce-0.12%$136.23 - $149.25
($142.86)
$ 165.2414%Reduce -2.76%3,330,000
BCRRay Dalio 2014-06-30 Reduce-0.02%$136.23 - $149.25
($142.86)
$ 165.2414%Reduce -36.59%27,386
BCRVanguard Health Care Fund 2014-06-30 Reduce-0.28%$136.23 - $149.25
($142.86)
$ 165.2414%Reduce -37.07%1,157,400
BCRVanguard Health Care Fund 2014-03-31 Add0.63%$125.42 - $146.57
($137.91)
$ 165.2417%Add 505.60%1,839,200
BCRRay Dalio 2014-03-31 Add0.03%$125.42 - $146.57
($138.12)
$ 165.2416%Add 118.27%43,186
BCRDonald Yacktman 2014-03-31 Reduce-0.51%$125.42 - $146.57
($137.91)
$ 165.2417%Reduce -11.96%6,827,627
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCR is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BCR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
RING TIMOTHY MChairman and CEO 2015-03-23Sell7,628$170.65-2.34view
BRESLAWSKY MARC CDirector 2015-02-24Sell7,200$174.37-4.42view
RING TIMOTHY MChairman and CEO 2015-02-23Sell20,000$176.33-5.48view
HOLLAND CHRISTOPHER SSenior Vice President and CFO 2015-02-20Sell16,091$176.03-5.32view
DeFord John ASr. VP Sci Tech and Clin Afrs 2015-02-20Sell2,987$174.85-4.68view
WEILAND JOHN HPresident and COO 2015-02-19Sell8,413$174.99-4.76view
Beasley Jim CGroup President 2015-02-19Sell2,884$174.79-4.65view
Groetelaars John PGroup Vice President 2015-02-19Sell4,566$175.14-4.84view
Luboff Sharon MGroup Vice President 2015-02-19Sell1,117$174.42-4.45view
Christian Patricia GVP -Quality, Reg & Med Affairs 2015-02-18Sell1,213$175.56-5.07view

Press Releases about BCR :

    Quarterly/Annual Reports about BCR:

    News about BCR:

    Articles On GuruFocus.com
    Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
    Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
    Teleflex Declares Its Quarter Four Results Feb 24 2015 
    Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
    Weekly 52-Week Highs Highlight: LBTYK, STZ, FISV, BCR Nov 09 2014 
    Dividend Aristocrats In Focus Part 19 of 54: CR Bard Oct 15 2014 
    Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
    Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
    No More a Simple Distributor Sep 07 2014 
    Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 

    More From Other Websites
    CryoLife, CR Bard War over Patent Infringement Continues - Analyst Blog Mar 13 2015
    Bard to Present at Barclays Global Healthcare Conference Mar 04 2015
    Bard to Present at Barclays Global Healthcare Conference Mar 04 2015
    CMS Approves Pass-Through Payment for Lutonix DCB for Outpatient Use Mar 03 2015
    BARD C R INC /NJ/ Financials Feb 25 2015
    Bard to Present at Raymond James Institutional Investors Conference Feb 25 2015
    Bard to Present at Raymond James Institutional Investors Conference Feb 25 2015
    Reversing a Declining Pattern in Earnings Per Share Feb 24 2015
    CR Bard's Lutonix DCB Gets Pass-Through Payment Approval - Analyst Blog Feb 23 2015
    CMS Approves Pass-Through Payment for Lutonix DCB for Outpatient Use Feb 19 2015
    BARD C R INC /NJ/ Files SEC form 10-K, Annual Report Feb 18 2015
    CryoLife (CRY) Down as Q4 Earnings Fall; Revenues Rise Y/Y - Analyst Blog Feb 18 2015
    C.R. Bard, Inc. -- Moody's downgrades C.R. Bard's long term rating to Baa1 from A3; outlook stable Feb 13 2015
    CR Bard, Boston Scientific Ink Lutonix Distribution Agreement - Analyst Blog Feb 10 2015
    Boston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix® Drug Coated Balloon Feb 09 2015
    Boston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix® Drug Coated Balloon Feb 09 2015
    Friday's Market Recap Jan 30 2015
    C.R. Bard Beats Q4 Earnings and Sales, 15' Outlook Cautious - Analyst Blog Jan 30 2015
    C R Bard Inc Earnings Call scheduled for 5:00 pm ET today Jan 29 2015
    Bard Announces Fourth Quarter Results Jan 29 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK